JP Patent

JP6227741B2 — ３−（６−（１−（２，２−ジフルオロベンゾ［ｄ］［１，３］ジオキソル−５−イル）シクロプロパンカルボキサミド）−３−メチルピリジン−２−イル）安息香酸の固体状形態

Assigned to Vertex Pharmaceuticals Inc · Expires 2017-11-08 · 9y expired

What this patent protects

Patent listed against Kalydeco.

Drugs covered by this patent

Kalydeco (IVACAFTOR) · Vertex Pharms Inc

Patent Metadata

Patent number: JP6227741B2
Jurisdiction: JP
Classification: —
Expires: 2017-11-08
Drug substance claim: No
Drug product claim: No
Assignee: Vertex Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.